Island Pharmaceuticals LtdASX: ILA

Quarterly Appendix 4C and Activities Report

Jul 29, 2026 at 7:47 PM EDT · Issued by Island Pharmaceuticals Ltd via ASX

Filed with ASX · Jul 29, 2026 at 7:47 PM EDT

On 6ix: 6ix.com/news/quarterly-appendix-4c-and-activities-report-7

Island Pharmaceuticals Limited ACN 641 183 842 | Registered office: Suite 1.01, 117 Camberwell Rd, Hawthorn East VIC 3123, Australia 30 July 2026 ASX Announcement June 2026 Quarterly Activities Report • GMP manufacturing of Galidesivir underway to support pivotal...

View Attachment

6ix hasn’t read this filing yet.

Island Pharmaceuticals Ltd on 6ix

Story so far

Appendix 4D & Half-Year Financial StatementsFeb 25, 2026
Quarterly Activities & Cashflow ReportApr 30, 2025
Quarterly Activity Report and Appendix 4CJan 31, 2024

Earlier from Island Pharmaceuticals

Texas Biomed SOW accelerates pivotal FDA pathwayJul 12
Investor Presentation - Ebola Clinical ProgramJul 7
Galidesivir approved for treatment use in in Ebola epidemicJul 6
Pause in TradingJul 2
Singapore Patent Expands Island's ISLA 101 Viral ProtectionJul 1

Later from Island Pharmaceuticals

Investor presentationAug 6
Application for quotation of securities - ILAAug 11
Cleansing NoticeAug 11
Date of AGM & Closing Date for Director NominationsAug 12
Island boosts Galidesivir supply as Ebola surgesAug 20

All Island Pharmaceuticals news releases

Follow Island Pharmaceuticals into a list and get an email when it puts out news.

Follow Island Pharmaceuticals